Arie Belldegrun - Teva Pharmaceutical Independent Director
| TEVA Stock | ILA 4,885 25.00 0.51% |
Director
Dr. Arie S. Belldegrun serves as Director at Teva Pharmaceutical Industries Limited since 2013. His work experience includes the following roles Director of the Institute of Urologic Oncology and Professor and Chief of Urologic Oncology at the David Geffen School of Medicine at the University of California, Los Angeles, where he has held the Roy and Carol Doumani Chair in Urologic Oncology since 2000, Chairman, President, Chief Executive Officer and Founder of Kite Pharma, Inc., Chairman of Arno Therapeutics, Inc., Chairman of TheraCoat Ltd., Director at SonaCare Medical LLC, Director at Nile Therapeutics Inc., Founder and Founding Chairman of Agensys, Inc., CoFounder and Founding Vice Chairman of the Board and Chairman of the Scientific Advisory Board at Cougar Biotechnology, Chairman and Partner of Two River Consulting, LLC., Chairman of the Molecular and Biological Technology Committee of the American Urological Association and Member of its Technology Assessment Council, Member of the Governors Council on Bioscience for the State of California biotechnology Group Leader of the Mayor of Los Angeles Economy and Jobs Committee and Author of more than 450 scientific publications since 2013.
| Age | 65 |
| Tenure | 11 years |
| Professional Marks | Ph.D |
| Phone | (972) 3 914 8213 |
| Web | www.tevapharm.com |
Arie Belldegrun Latest Insider Activity
Tracking and analyzing the buying and selling activities of Arie Belldegrun against Teva Pharmaceutical stock is an integral part of due diligence when investing in Teva Pharmaceutical. Arie Belldegrun insider activity provides valuable insight into whether Teva Pharmaceutical is net buyers or sellers over its current business cycle. Note, Teva Pharmaceutical insiders must abide by specific rules, including filing SEC forms every time they buy or sell Teva Pharmaceutical'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Arie Belldegrun over three weeks ago Acquisition by Arie Belldegrun of 4710121 shares of Allogene Therapeutics subject to Rule 16b-3 | ||
Arie Belldegrun over a month ago Acquisition by Arie Belldegrun of 4710120 shares of Allogene Therapeutics subject to Rule 16b-3 |
Teva Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of 0.0363 % which means that it generated a profit of $0.0363 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2414) %, meaning that it generated substantial loss on money invested by shareholders. Teva Pharmaceutical's management efficiency ratios could be used to measure how well Teva Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Ruth Arnon | Compugen | 86 | |
| Joshua Shemer | Compugen | 63 | |
| Dov Hershberg | Compugen | 74 | |
| Yehuda Reznik | Bonus Biogroup | 68 | |
| Batia Avital | Bonus Biogroup | 54 | |
| Eran Perry | Compugen | N/A | |
| Daniel BenLulu | Bonus Biogroup | 54 | |
| Avi Slonim | Bonus Biogroup | 38 | |
| Kinneret Savitsky | Compugen | 50 | |
| Michal Preminger | Compugen | N/A | |
| Gilead Halevy | Compugen | 51 | |
| Arie Ovadia | Compugen | 67 | |
| Rachel Ari | Bonus Biogroup | 55 | |
| JeanPierre Bizzari | Compugen | 64 | |
| Gil Shapira | Bonus Biogroup | 56 | |
| Sanford Zweifach | Compugen | 60 | |
| Yair Aharonowitz | Compugen | 73 | |
Management Performance
| Return On Equity | -0.24 | |||
| Return On Asset | 0.0363 |
Teva Pharmaceutical Leadership Team
Elected by the shareholders, the Teva Pharmaceutical's board of directors comprises two types of representatives: Teva Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Teva. The board's role is to monitor Teva Pharmaceutical's management team and ensure that shareholders' interests are well served. Teva Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Teva Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Moshe Many, Independent Director | ||
| Richard Daniell, Executive Vice President - European Commercial | ||
| Mark Sabag, Executive Vice President, Chief Human Resources Officer and Global Communications and Brand | ||
| Ronit SatchiFainaro, Independent Director | ||
| Richard Lerner, Independent Director | ||
| Galia Maor, Independent Director | ||
| Janet Vergis, Independent Director | ||
| Carlo Notaristefani, CEO of Global Operations and President of Global Operations | ||
| JeanMichel Halfon, Statutory - independent director | ||
| Eli Shani, Ex Portfolio | ||
| Dipankar Bhattacharjee, Senior Vice President CFO Americas and Head of Finance Operations | ||
| Abbas Hussain, Independent Director | ||
| Yitzhak Peterburg, Director | ||
| Hafrun Fridriksdottir, Executive Vice President and Presidentident of Global Generics R&D | ||
| Perry Nisen, Independent Director | ||
| Isaac Abravanel, Group Executive Vice President Teva Corporate in Israel and Global Community Alliances, Director | ||
| David Stark, Executive Vice President, Chief Legal Officer | ||
| Amir Elstein, Vice Chairman of the Board | ||
| Dan Suesskind, Director | ||
| Arie Belldegrun, Independent Director | ||
| Richard Egosi, Chief Legal Officer and Group Executive VP | ||
| Andrew Weil, Chief Accounting Officer | ||
| Jean Halfon, Statutory - independent director | ||
| Sven Dethlefs, Executive Vice President - Global Marketing & Portfolio | ||
| Robert Koremans, President CEO-Global Specialty Medicines | ||
| Gerald Lieberman, Independent Director | ||
| Roberto Mignone, Independent Director | ||
| Rosemary Crane, Independent Director | ||
| Nechemia Peres, Independent Director | ||
| Roger Abravanel, Independent Director | ||
| Eyal Desheh, CFO and Group Executive VP | ||
| Gianfranco Nazzi, Executive Vice President - International Markets Commercial | ||
| Kare Schultz, CEO Pres | ||
| Iris BeckCodner, Group Executive Vice President - Corporate Marketing Excellence and Communication | ||
| Amir Weiss, VP Officer | ||
| Brendan OGrady, Executive Vice President - North America Commercial | ||
| Michael Hayden, President - Global Research and Development, Chief Scientific Officer | ||
| Gabrielle Sulzberger, Statutory Independent Director | ||
| Eric Drape, Executive Vice President - Global Operations | ||
| Erez Vigodman, CEO and President Director and Member of Fin. and Invesment Committee | ||
| Eliyahu Kalif, Chief Financial Officer, Executive Vice President, Director | ||
| Kathleen Veit, Global VP | ||
| Joseph Nitzani, Independent Director | ||
| Deborah Griffin, Chief Accounting Officer | ||
| Timothy Wright, Head - Business Development, Strategy and Innovation | ||
| Sigurdur Olafsson, President and CEO - Global Generic Medicines Group | ||
| Murray Goldberg, Independent Director | ||
| Dan Propper, Independent Director | ||
| Ory Slonim, Independent Director | ||
| Michael McClellan, Chief Financial Officer, Executive Vice President | ||
| Kevin Mannix, Vice President Head of Investor Relations | ||
| Kaare Schultz, President, Chief Executive Officer, Director | ||
| Sol Barer, Independent Chairman of the Board | ||
| Eli Kalif, Chief Financial Officer, Executive Vice President, Director |
Teva Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Teva Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.24 | |||
| Return On Asset | 0.0363 | |||
| Profit Margin | (0.16) % | |||
| Operating Margin | 0.18 % | |||
| Current Valuation | 102.13 B | |||
| Shares Outstanding | 1.11 B | |||
| Shares Owned By Insiders | 0.77 % | |||
| Shares Owned By Institutions | 5.30 % | |||
| Price To Book | 1.18 X | |||
| Price To Sales | 2.32 X |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Teva Pharmaceutical Industries. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for Teva Stock analysis
When running Teva Pharmaceutical's price analysis, check to measure Teva Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Teva Pharmaceutical is operating at the current time. Most of Teva Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Teva Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Teva Pharmaceutical's price. Additionally, you may evaluate how the addition of Teva Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |